Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50747
Name lymphoplasmacytic lymphoma
Definition A B-cell lymphocytic neoplasm characterized by an uncontrolled increase of B-cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma lymphoplasmacytic lymphoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00577278 Phase II Ibritumomab tiuxetan Methotrexate + Sirolimus + Tacrolimus Rituximab Fludarabine + Melphalan Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed USA 0
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated USA 0
NCT01732913 Phase III Idelalisib Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated USA | ITA | FRA | ESP | DEU 14
NCT01732926 Phase III Idelalisib Bendamustine + Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated USA | ITA | FRA | ESP | DEU | CAN 9
NCT01796171 Phase Ib/II Lilotomab Betalutin Rituximab A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) Active, not recruiting USA | ITA | FRA | ESP | CAN | BEL | AUT 17
NCT01955499 Phase I Ibrutinib + Lenalidomide Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Active, not recruiting USA | CAN 0
NCT01994382 Phase I Cerdulatinib Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma Completed USA 0
NCT02000934 Phase I Mivavotinib A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies Completed USA | ITA | ESP 1
NCT02049541 Phase I Buparlisib + Rituximab Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma Completed USA 0
NCT02092909 Phase Ib/II Bazlitoran Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (8400-401) Terminated USA 0
NCT02106091 Phase I AFM11 Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL Terminated USA | DEU 2
NCT02180724 Phase I Acalabrutinib An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenström Macroglobulinemia Active, not recruiting USA | ITA | FRA | ESP 3
NCT02367040 Phase III Rituximab Copanlisib Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 30
NCT02369016 Phase III Copanlisib Phase III Copanlisib in Rituximab-refractory iNHL Active, not recruiting ITA 9
NCT02384954 Phase Ib/II ALT-803 + Rituximab ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab Terminated USA 0
NCT02604511 Phase II Ibrutinib Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing Active, not recruiting USA 0
NCT02626455 Phase III Vincristine Sulfate Prednisone Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib Bendamustine + Rituximab Rituximab Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 28
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting USA 0
NCT02950220 Phase I Ibrutinib + Pembrolizumab Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed USA 0
NCT03010358 Phase Ib/II Entospletinib + Obinutuzumab Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Completed USA 0
NCT03015896 Phase Ib/II Lenalidomide + Nivolumab Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Recruiting USA 0
NCT03037645 Phase Ib/II Vecabrutinib Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers Terminated USA 0
NCT03053440 Phase III Ibrutinib Zanubrutinib A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Completed USA | ITA | FRA | ESP | DEU | BEL 7
NCT03133221 Phase II Idelalisib 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Active, not recruiting USA 0
NCT03225716 Phase Ib/II Ibrutinib + Ulocuplumab A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia Active, not recruiting USA 0
NCT03277729 Phase Ib/II CD20 CAR T-cells + Cyclophosphamide + Fludarabine A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Recruiting USA 0
NCT03479268 Phase I Ibrutinib + MLN4924 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT03498612 Phase II Pembrolizumab Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases Recruiting USA 0
NCT03506373 Phase II Ibrutinib + Ixazomib Ibrutinib and Ixazomib Citrate in Treating Participants With Relapsed or Refractory Waldenstrom Macroglobulinemia Active, not recruiting USA 0
NCT03537482 Phase I APG-2575 APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies Recruiting USA 1
NCT03571828 Phase I AMG562 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma Completed USA | DEU | CAN | BEL 0
NCT03601819 Phase I Pacritinib Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Terminated USA 0
NCT03679624 Phase II Daratumumab + Ibrutinib Daratumumab Plus Ibrutinib in Patients With Waldenstrom's Macroglobulinemia Recruiting USA 0
NCT03711578 Phase II Tenalisib Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) Completed USA 1
NCT03833180 Phase I VLS-101 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies Recruiting USA 0
NCT03884998 Phase I Copanlisib + Nivolumab Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma Recruiting USA 0
NCT04043845 Phase I Ibrutinib + LY3214996 ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies Withdrawn 0
NCT04401020 Phase I SAR442257 First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL Recruiting USA | ESP 3
NCT04578600 Phase I Azacitidine + Lenalidomide + Obinutuzumab CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Recruiting USA 0
NCT04799275 Phase II Azacitidine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Suspended USA 0
NCT04840602 Phase II Ibrutinib + Rituximab + Venetoclax Ibrutinib + Rituximab Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma Suspended USA 0
NCT04883437 Phase II Acalabrutinib + Obinutuzumab Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Recruiting USA 0
NCT05256641 Phase Ib/II Acalabrutinib Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma Not yet recruiting USA 0